Fapresor Dosage/Direction for Use

Myocardial Infarction: Early treatment: During the early phase of definite acute myocardial infarction, treatment with Metoprolol tartrate can be initiated as soon as possible after the patients arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patients hemodynamic condition has stabilized.
Treatment in this early phase should begin with the intravenous administration of three bolus injections of 5 mg of Metoprolol tartrate each; the injections should be given approximately 2-minute intervals. During the intravenous administration of Metoprolol tartrate, blood pressure, heart rate, and electrocardiogram should be carefully monitored.
In patients who tolerate the full intravenous dose (15 mg), Metoprolol tartrate tablets, 50 mg every 6 hours, should be initiated 15 minutes after the last intravenous dose and continued for 48 hours. Thereafter, patients should receive a maintenance dosage (see Late Treatment as follows).
Patient who appear not to tolerate the full intravenous dose should started on metoprolol tartrate tablets either 25 mg or 50 mg every 6 hours (depending on the degree of intolerance) 15 minutes after the last intravenous dose as soon as their clinical condition allows. In patients with severe intolerance, treatment with metoprolol tartrate should be discontinued. (see Warnings).
Late Treatment: Patients with contraindications to treatment during the early phase of suspected or definite myocardial infarction, patients who appear not to tolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other reason should be started on Metoprolol tartrate tablets, 100 mg twice daily, as soon as their clinical condition allows. Therapy should be continued for at least 3 months. Although the efficacy of Metoprolol tartrate beyond 3 months has not been conclusively established, data from studies with other beta blockers suggest that treatment should be continued for 1-3 years.
Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.